Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Immortals vs Trinity Meds

Immortals
Graded #286

Higher grade

vs+0.5999999999999943
Trinity Meds
Graded #302

Lower grade

The verdict

Immortals takes it — 61.8/100 to 61.2/100, but only just.

Immortals grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Immortals is a LegitScript-certified longevity telehealth platform founded by Bryan Johnson, offering compounded semaglutide (Semaglutide/Glycine/B12) and tirzepatide (Tirzepatide/Glycine/B12) as microdose… Trinity Meds is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrinity Meds +10
54
64
Dose & formulationEven
64
64
Clinical oversightImmortals +14
88
74
Labs & monitoringImmortals +2
54
52
FulfillmentEven
68
68
Contract termsEven
20
20
Immortals · left barTrinity Meds · right bar

The numbers

MetricImmortalsTrinity Meds
WeighScore61.8/10061.2/100
GradeCC
Scorecard rank#286#302
Semaglutide$167/mo (microdose tier, compounded)$149/mo (compounded)
Tirzepatide$180/mo (microdose tier, compounded)$199/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Immortals

Graded #286 · C

Strengths

  • LegitScript certified (ID 50458743) with board-certified U.S. physician review within 72 hours
  • Physician consult + prescription bundled in price — 'You pay for treatment. That's it' with no added fees
  • Competitive pricing: semaglutide microdose from $167/month, tirzepatide from $180/month (promotional)
  • Unlimited provider messaging for 12 months included; video consults available
  • Founded by Bryan Johnson and Kate Tolo; clinical lead Dr. Carl Seger, M.D. (preventive/longevity medicine)

Where it loses points

  • Microdose framing uses sub-clinical doses — lower weight-loss efficacy than standard GLP-1 protocols
  • Quarterly commitment only — 3-month minimum, paid upfront ($501–$540/quarter); no monthly flexibility
  • State availability not publicly listed; 'eligible U.S. states' with no specific state list
  • Labs not included; baseline bloodwork protocol not disclosed on any public page
  • Compounding pharmacy not named; no 503A/503B accreditation details disclosed
Trinity Meds

Graded #302 · C

Strengths

  • All-inclusive flat pricing — $149/month semaglutide, same price at every dose, no hidden fees
  • Multi-month plans cut the cost further (semaglutide to $129/month, tirzepatide to $149/month)
  • No insurance required, FSA eligible, with free shipping to your door
  • Named operating entity (Trinity Meds Inc) and US-licensed clinicians via CareValidate Health

Where it loses points

  • Doesn't publish the states it serves — you only learn eligibility after starting the assessment
  • Pharmacy partners are described as 'multiple USA certified pharmacies' but none are named
  • No terms-of-service page is posted (only a privacy policy)
  • Compounded semaglutide and tirzepatide only — no brand-name or oral options
  • Military framing is marketing; the program and pricing are open to anyone who qualifies

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard